Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
|
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 50 条
  • [1] QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
    Fatima, Shehnaz
    Pal, Divyani
    Agarwal, Subhash Mohan
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (01) : 1306 - 1315
  • [2] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
    Hoogenboom, Niels
    Demont, Dennis
    de Zwart, Edwin
    Verkaik, Saskia
    Emmelot, Maaike
    van de Kar, Bas
    Kaptein, Allard
    Barf, Tjeerd
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
  • [3] Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
    Bello, Martiniano
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 118 : 1948 - 1962
  • [4] Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
    Saldana-Rivera, Lucia
    Bello, Martiniano
    Mendez-Luna, David
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (17): : 4671 - 4684
  • [5] Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
    Sogabe, Satoshi
    Kawakita, Youichi
    Igaki, Shigeru
    Iwata, Hidehisa
    Miki, Hiroshi
    Cary, Douglas R.
    Takagi, Terufumi
    Takagi, Shinji
    Ohta, Yoshikazu
    Ishikawa, Tomoyasu
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (02): : 201 - 205
  • [6] Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR
    Donghui Huo
    Hongzhao Wang
    Zijian Qin
    Yujia Tian
    Aixia Yan
    Molecular Diversity, 2022, 26 : 1715 - 1730
  • [7] Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR
    Huo, Donghui
    Wang, Hongzhao
    Qin, Zijian
    Tian, Yujia
    Yan, Aixia
    MOLECULAR DIVERSITY, 2022, 26 (03) : 1715 - 1730
  • [8] Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR
    Todsaporn, Duangjai
    Zubenko, Alexander
    Kartsev, Victor G.
    Mahalapbutr, Panupong
    Geronikaki, Athina
    Sirakanyan, Samvel N.
    Divaeva, Lyudmila N.
    Chekrisheva, Victoria
    Yildiz, Ilkay
    Choowongkomon, Kiattawee
    Rungrotmongkol, Thanyada
    JOURNAL OF PHYSICAL CHEMISTRY B, 2024, 128 (50): : 12389 - 12402
  • [9] Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations
    Xiao, Zhen
    Zhou, Zhihui
    Chu, Cilong
    Zhang, Qian
    Zhou, Lingjia
    Yang, Zunhua
    Li, Xin
    Yu, Liying
    Zheng, Pengwu
    Xu, Shan
    Zhu, Wufu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 203
  • [10] Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Wurz, Ryan P.
    Pettus, Liping H.
    Ashton, Kate
    Brown, James
    Chen, Jian Jeffrey
    Herberich, Brad
    Hong, Fang-Tsao
    Hu-Harrington, Essa
    Nguyen, Tom
    St Jean, David J., Jr.
    Tadesse, Seifu
    Bauer, David
    Kubryk, Michele
    Zhan, Jinghui
    Cooke, Keegan
    Mitchell, Petia
    Andrews, Kristin L.
    Hsieh, Faye
    Hickman, Dean
    Kalyanaraman, Nataraj
    Wu, Tian
    Reid, Darren L.
    Lobenhofer, Edward K.
    Andrews, Dina A.
    Everds, Nancy
    Guzman, Roberto
    Parsons, Andrew T.
    Hedley, Simon J.
    Tedrow, Jason
    Thiel, Oliver R.
    Potter, Matthew
    Radinsky, Robert
    Beltran, Pedro J.
    Tasker, Andrew S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (09): : 987 - 992